Atherosclerosis and aortic stenosis almost always coexist in clinical practice; therefore, the three groups of drugs- statins, inhibitors of the renin-angiotensin axis, and PCSK9 inhibitors–deserve their place and indication in patients with aortic stenosis. This evidence concerns the gene PCSK9 and atherosclerosis.